13 assets in Neoplasm Of Thorax

Therapeutic assets addressing Neoplasm Of Thorax, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Neoplasm Of Thorax	Fundación GECP	P3	BB (65)
Cis-Diamminedichloroplatinum Ii Neoplasm Of Thorax	Nanfang Hospital, Southern Medical University	P3	B (61)
Pembrolizumab Neoplasm Of Thorax	Amgen	P3	B (60)
Adebrelimab Neoplasm Of Thorax	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Atezolizumab Neoplasm Of Thorax	Fundación GECP	P2	CCC (53)
Etoposide Neoplasm Of Thorax	Nanfang Hospital, Southern Medical University	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Neoplasm Of Thorax	Fundación GECP	P2	CCC (53)
Teniposide Neoplasm Of Thorax	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (53)
Tarlatamab Neoplasm Of Thorax	Fundación GECP	P2	CCC (49)
Anvumetostat Neoplasm Of Thorax	Amgen	P1	CC (43)
Sotorasib Neoplasm Of Thorax	Amgen	P1	CC (43)
Blu-701 Neoplasm Of Thorax	Blueprint Medicines Corporation	P1	CC (41)
Osimertinib Neoplasm Of Thorax	Blueprint Medicines Corporation	P1	CC (41)